Alicja N. Skowron
Research Subjects
Alicja N. Skowron has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Daria Gajewska
Captor Therapeutics Inc. Wrocław Poland
4 shared publications- Janusz Wiśniewski
Captor Therapeutics Inc. Wrocław Poland
4 shared publications - Karolina M. Górecka-Minakowska
Captor Therapeutics Inc. Wrocław Poland
4 shared publications Magdalena Sypień
Captor Therapeutics Inc. Wrocław Poland
4 shared publications- Marta Klejnot
Captor Therapeutics Inc. Wrocław Poland
4 shared publications - Martyna W. Pastok
Captor Therapeutics Inc. Wrocław Poland
4 shared publications
Latest Publications
- 14 April 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (7)
Cover Feature: Ligand‐Induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4 (ChemMedChem 7/2026)
- 14 April 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (7)
Cover Feature: Ligand‐Induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4 (ChemMedChem 7/2026)
- Open Access
- 3 April 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (7) , e202500849
Ligand‐Induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4
The application of targeted protein degradation is currently constrained by the limited availability of low‐molecular‐weight molecules that can recruit E3 ligases other than CRBN (Cereblon) or VHL (von Hippel–Lindau ligase). In this study, we present the structure‐based drug design of high‐affinity ligands that engage E3 ligase GID4 (glucose‐induced degradation protein 4) in biophysical and cellular experiments. Through structural studies and molecular modeling, we identified three clusters of compounds that induce distinct conformations of GID4. We characterized potential exit vectors and used the most promising ligand as a building block to prepare bifunctional degraders in the form of proteolysis‐targeting chimeras (PROTACs). Although ternary complex formation was successful in vitro, degradation of BRD4 was not observed, highlighting the need for further optimization of the degraders. Finally, we theoretically investigated the likelihood of the identified GID4 conformations participating in protein–protein interactions mediated by molecular glue mechanisms. We believe the expanded ligand diversity discovered in this study may pave the way for tuning the selectivity and efficacy of interactions involving GID4 and its neosubstrates.
- 3 April 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (7) , e202500849
Open AccessLigand‐Induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4
The application of targeted protein degradation is currently constrained by the limited availability of low‐molecular‐weight molecules that can recruit E3 ligases other than CRBN (Cereblon) or VHL (von Hippel–Lindau ligase). In this study, we present the structure‐based drug design of high‐affinity ligands that engage E3 ligase GID4 (glucose‐induced degradation protein 4) in biophysical and cellular experiments. Through structural studies and molecular modeling, we identified three clusters of compounds that induce distinct conformations of GID4. We characterized potential exit vectors and used the most promising ligand as a building block to prepare bifunctional degraders in the form of proteolysis‐targeting chimeras (PROTACs). Although ternary complex formation was successful in vitro, degradation of BRD4 was not observed, highlighting the need for further optimization of the degraders. Finally, we theoretically investigated the likelihood of the identified GID4 conformations participating in protein–protein interactions mediated by molecular glue mechanisms. We believe the expanded ligand diversity discovered in this study may pave the way for tuning the selectivity and efficacy of interactions involving GID4 and its neosubstrates.
- Open Access
A Robust Crystallographic Platform for High-Throughput β-Catenin Ligand Discovery
This study presents a robust crystallographic platform for assessing compounds binding to β-catenin. We developed a standardized protein production protocol for the armadillo domain of β-catenin (BC-ARM) and performed biophysical screens using Surface Plasmon Resonance (SPR) and Differential Scanning Fluorimetry (DSF). These findings led to the successful determination of the co-crystal structure of BC-ARM with compound 1 binding to previously reported site but distinct from known transcription factor binding sites. To broaden the search for novel BC binding sites, we utilized FragLites library with a cyclic peptide-stabilized BC-ARM construct. This yielded two high-resolution co-crystal structures identifying a previously unreported binding hotspot. Recognizing the limitations of the cyclic peptide-bound construct for general screening, we designed a novel, truncated BC-ARM construct. This new construct eliminates unstructured regions, reliably producing high-quality, diffracting crystals suitable for high-throughput crystallographic studies. In conclusion, the ligand-bound β-catenin structures and this novel, robust BC-ARM construct establish a powerful platform for further β-catenin investigation.
Open AccessA Robust Crystallographic Platform for High-Throughput β-Catenin Ligand Discovery
This study presents a robust crystallographic platform for assessing compounds binding to β-catenin. We developed a standardized protein production protocol for the armadillo domain of β-catenin (BC-ARM) and performed biophysical screens using Surface Plasmon Resonance (SPR) and Differential Scanning Fluorimetry (DSF). These findings led to the successful determination of the co-crystal structure of BC-ARM with compound 1 binding to previously reported site but distinct from known transcription factor binding sites. To broaden the search for novel BC binding sites, we utilized FragLites library with a cyclic peptide-stabilized BC-ARM construct. This yielded two high-resolution co-crystal structures identifying a previously unreported binding hotspot. Recognizing the limitations of the cyclic peptide-bound construct for general screening, we designed a novel, truncated BC-ARM construct. This new construct eliminates unstructured regions, reliably producing high-quality, diffracting crystals suitable for high-throughput crystallographic studies. In conclusion, the ligand-bound β-catenin structures and this novel, robust BC-ARM construct establish a powerful platform for further β-catenin investigation.
- Open Access
Ligand-induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4
The application of targeted protein degradation (TPD) is currently constrained by the limited availability of low-molecular-weight molecules that can recruit E3 ligases other than CRBN (Cereblon) or VHL (Von Hippel-Lindau ligase). In this study, we present the structure-based drug design (SBDD) of high-affinity ligands that engage E3 ligase GID4 (Glucose-induced degradation protein 4) in biophysical and cellular experiments. Through structural studies and molecular modeling, we identified three clusters of compounds that induce distinct conformations of GID4. We characterized potential exit vectors and used the most promising ligand as a building block to prepare bifunctional degraders in the form of proteolysis-targeting chimeras (PROTACs). Although ternary complex formation was successful in vitro , degradation of BRD4 was not observed, highlighting the need for further optimization of the degraders. Finally, we theoretically investigated the likelihood of the identified GID4 conformations participating in protein-protein interactions mediated by molecular glue mechanisms. We believe the expanded ligand diversity discovered in this study may pave the way for tuning the selectivity and efficacy of interactions involving GID4 and its neosubstrates. GRAPHICAL
Open AccessLigand-induced Conformational Plasticity of the CTLH E3 Ligase Receptor GID4
The application of targeted protein degradation (TPD) is currently constrained by the limited availability of low-molecular-weight molecules that can recruit E3 ligases other than CRBN (Cereblon) or VHL (Von Hippel-Lindau ligase). In this study, we present the structure-based drug design (SBDD) of high-affinity ligands that engage E3 ligase GID4 (Glucose-induced degradation protein 4) in biophysical and cellular experiments. Through structural studies and molecular modeling, we identified three clusters of compounds that induce distinct conformations of GID4. We characterized potential exit vectors and used the most promising ligand as a building block to prepare bifunctional degraders in the form of proteolysis-targeting chimeras (PROTACs). Although ternary complex formation was successful in vitro , degradation of BRD4 was not observed, highlighting the need for further optimization of the degraders. Finally, we theoretically investigated the likelihood of the identified GID4 conformations participating in protein-protein interactions mediated by molecular glue mechanisms. We believe the expanded ligand diversity discovered in this study may pave the way for tuning the selectivity and efficacy of interactions involving GID4 and its neosubstrates. GRAPHICAL